Journals / MN Kardiyoloji / 2019 / Cilt: 26 - Sayı: 4

Cardiac Implantable Device Experience in the Cardilogy Clinic of a Tertiary University Hospital

Üçüncü Basamak Üniversite Hastanesi Kardiyoloji Kliniğinin Kalp Pili ve Diğer İmplante Edilebilen Kardiyak Cihaz İmplantasyonu Tecrübesi

Pages
240–247
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall complication rate was 8.8%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the types of cardiac rhythm devices implanted in last 5 years, the characteristics of the procedure, the techniques used in the procedure, the complications of the procedure and the infections associated with the device implantation.
📊
Key Findings & Data:Material and Method: A retrospective screening was conducted including the dates January 1, 2014 and January 31, 2019.
💡
Conclusion & Impact:The overall complication rate was 8.8%.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the types of cardiac rhythm devices implanted in last 5 years, the characteristics of the procedure, the techniques used in the procedure, the complications of the procedure and the infections associated with the device implantation. Material and Method: A retrospective screening was conducted including the dates January 1, 2014 and January 31, 2019. The clinical features of the patients whose data were available, the indications of the device, the characteristics of the procedure and the complications during and after the procedure were evaluated. Results: A record of 375 patients was reached. The median age of the patients was 70 (60-78), and 63.7% of them were male. While implantation of pacemaker was performed in 43.2% of the patients, implantable cardioverter defibrillator and cardiac resynchronization therapy-defibrillator device implantation were performed in 45% (n = 169). 11.8% of all procedures were device generator replacements (n=44). The indications for pacemaker implantation were AV blocks (72,8%) and sinus nodal problems and the sick sinus syndrome (27,2%). The indications for implantable cardioverter defibrillator and cardiac resynchronization therapy-defibrillator were respectively ischemic cardiomyopathy (65.08%), dilated cardiomyopathy (29.58%), hypertrophic cardiomyopathy (4.14%), long QT syndrome (0.6%) and Brugada syndrome (0.6%). The overall complication rate was 8.8%. The most common complications were the need for battery pocket and lead revision, hemorrhage and hematoma, pneumothorax, battery pocket infection, and infective endocarditis and pericardial effusion. Conclusion: In our center, pacemakers and other implantable cardiac devices are implanted successfully and with similar complication rates as the current literature.

Özet

Amaç: Merkezimizde son 5 yıl içerisinde implante edilen kardiyak ritim düzenleyici cihazların çeşitlerini, işlem özelliklerini ve tekniklerini, işlem sırasında-sonrasında oluşan komplikasyonları belirlemektir. Gereç ve Yöntem: 1 Ocak 2014 ve 31 Ocak 2019 tarihlerini kapsayacak şekilde retrospektif bir tarama yapıldı. Verilerine ulaşılabilen hastaların klinik özellikleri, cihaz uygulama endikasyonları, işlem özellikleri, işlem sırasında ve sonrasında yaşanan komplikasyonları değerlendirildi. Bulgular: 375 kardiyak implante edilebilir cihaz işlemi hastasının kaydına ulaşıldı. Hastaların ortanca yaşları 70 (60-78) iken, %63,7’si ise erkek idi. Hastaların %43.2’sine kalp pili implantasyonu yapılırken (n=162), %45’ine implante edilebilir kardiyoverter defibrilatör ve kardiyak resenkronizasyon terapisi-defibrilatör cihazı implantasyonu yapılmıştır(n=169). İşlemlerin %11,8’ini ise cihaz jeneratör replasmanları oluşturmakta idi (n=44). Kalp pili endikasyonları, AV bloklar (%72,8) ve sinüs nodal problemler ve hasta sinüs sendromu (%27,2) idi. İmplante edilebilir kardiyoverter defibrilatör ve kardiyak resenkronizasyon terapisi-defibrilatör endikasyonları sırası ile iskemik kardiyomiyopati (%65,08), dilate kardiyomiyopati (%29,58), hipertrofik kardiyomiyopati (%4,14), uzun QT sendromu (%0,6) ve Brugada send romu (%0,6) idi. İşlemlerin tüm kısa ve uzun dönemli komplikasyon oranı %8,8 idi. En sık görülen komplikasyonlar sırası ile pil cebi ve lead revizyonu, kanama ve hematom, pnömotoraks, pil cebi enfeksiyonu, enfektif endokardit ve perikardiyal efüzyon idi. Sonuç: Merkezimizde kalp pilleri ve diğer implante edilebilen kardiyak cihazlar başarı ile ve güncel literatürle benzer komplikasyon oranları ile implante edilmektedir.

🔖

Cite This Article

TUNÇEZ, A., YALÇIN, M. U., TEZCAN, H., POLAT, O. C., ALTUNKESER, B. B. (2019). Cardiac Implantable Device Experience in the Cardilogy Clinic of a Tertiary University Hospital. MN Kardiyoloji, Cilt: 26 - Sayı: 4, 240–247. https://ajindex.com/articles/293755

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Larsson B, Elmqvist H, Ryden L, Schuller H. Lessons from the first patient with an implanted pacemaker: 1958-2001. Pace. 2003;26(1):114-24
  2. Mirowski M, Reid PR, Mower MM, et al. Termination of Malignant Ventricular Arrhythmias with an Implanted Automatic Defibrillator in Human-Beings. New Engl J Med. 1980;303(6):322-4
  3. Cazeau S RP, Bakdach S, Lazarus A, Limousin M, Henao L, Mundler O, Daubert JC, Mugica J. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994;17:1974-9
  4. Raatikainen MJP, Arnar DO, Merkely B. et al. A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Proce - dures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. Europace. 2017;19:1-90
  5. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975
  6. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41): 2793-867
  7. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29): 2281-329
  8. Ector H, Vardas P, Assoc E. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Eur Heart J. 2007;9(Suppl I):I44-9
  9. Liang JJ, Schaller RD, Modi DS, Enriquez A, Supple GE, Cooper JM. Low lateral thoracic site for cardiac implantable electronic device implantation: A viable alternative in patients with limited access options after infected device extraction. Heart